Stockscreener 앱 받기
0.6552
2.67%
-0.018
Skye Bioscience Inc 주식(SKYE)의 최신 뉴스
Skye Bioscience Faces Nasdaq Listing Compliance Deficiency Notice - TipRanks
Skye Bioscience receives Nasdaq notice for minimum bid price deficiency - Investing.com
Skye Bioscience Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq warns Skye Bioscience (SKYE) after shares stay under $1 minimum - Stock Titan
Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategy - MSN
Analysts Offer Insights on Healthcare Companies: Skye Bioscience (SKYE) and Sandoz Group Ltd (OtherSDZXF) - The Globe and Mail
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pio - GuruFocus
Cantor Fitzgerald reiterates Skye Bioscience stock rating at Neutral By Investing.com - Investing.com Canada
Citizens reiterates Skye Bioscience stock rating on weight loss data By Investing.com - Investing.com Canada
Skye Bioscience (SKYE) Advances Nimacimab Development with Promi - GuruFocus
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ... By GuruFocus - Investing.com Canada
Skye Bioscience Q4 2025 Earnings Call Transcript - MarketBeat
SKYE: Additive weight loss and durable efficacy drive nimacimab's advancement as a GLP-1 add-on - TradingView
Skye Bioscience, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:SKYE) 2026-03-10 - Seeking Alpha
Earnings call transcript: Skye Bioscience Q4 2025 highlights clinical advancements - Investing.com
Skye Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Skye (SKYE) Reinforces Nimacimab Strategy with Promising Data - GuruFocus
Q4 and full year results reveal momentum, Skye Bioscience, Inc. asserts - Traders Union
Skye Bioscience 2025 10-K: Net loss $(55.9M), Loss per share $(1.41) - TradingView
Skye Bioscience (NASDAQ: SKYE) highlights nimacimab obesity and metabolic pipeline - Stock Titan
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - ChartMill
Skye Bioscience Q4 2025 earnings preview - MSN
A Peek at Skye Bioscience's Future Earnings - Benzinga
Skye confirms phase 2 data on nimacimab for obesity expected later this year - MSN
Growth Value: Will Skye Bioscience Inc benefit from government policyQuarterly Portfolio Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Market Recap: Can Skye Bioscience Inc weather a recessionEarnings Growth Summary & Risk Managed Investment Strategies - baoquankhu1.vn
Growth Report: What are the analyst revisions for Skye Bioscience IncIs KNSL stock a good investment in YEARVolume Spike & Low Volatility Stock Suggestions - baoquankhu1.vn
Does Skye Bioscience Inc have a competitive edgeJuly 2025 Catalysts & Low Drawdown Momentum Ideas - baoquankhu1.vn
Smart Money: Can Skye Bioscience Inc beat the S P 5002025 Stock Rankings & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Risk Report: Whats the outlook for Skye Bioscience Incs sectorJuly 2025 Closing Moves & Expert Curated Trade Ideas - baoquankhu1.vn
Skye Bioscience Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Aug Intraday: Is Skye Bioscience Inc in a bullish channelQuarterly Earnings Report & Long-Term Safe Investment Plans - baoquankhu1.vn
Breakout Zone: Will Skye Bioscience Inc outperform the market in YEARIPO Watch & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026 - Sahm
Why Did Skye Bioscience Stock Plummet A Whopping 60% Today? - Stocktwits
Skye Bioscience schedules March 2026 earnings release with Q4 and full-year results - Traders Union
Skye Bioscience to Release 2025 Financial Results and Business Update on March 10, 2026 - geneonline.com
Skye Bioscience : Corporate Presentation View Presentation ( 260221 Skye Corporate Presentation ) - marketscreener.com
Skye Bioscience Stock Quote, Share Price, News and Analysis - Longbridge
SKYE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bull Run: Can Skye Bioscience Inc weather a recessionWeekly Stock Recap & Safe Entry Zone Identification - baoquankhu1.vn
Volume Summary: Should I hold or sell FATBP nowJuly 2025 Drop Watch & Risk Managed Investment Signals - baoquankhu1.vn
10 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
SKYE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
SKYE Earnings History & Surprises | EPS & Revenue Results | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill
Skye Bioscience says Kaitlyn Arsenault to step down as CFO effective Feb 20 - marketscreener.com
CFO exits Skye Bioscience (SKYE) with $450k severance; CEO takes accounting duties - Stock Titan
2026-02-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Skye Bioscience, Inc. (SKYE) and Encourages Shareholders to Learn More About the Investigation | NDAQ:SKYE | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Skye Bioscience, Inc. (SKYE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2026-02-17 | Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:SKYE | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2026-02-15 | Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Shareholders to Inquire about Securities Investigation | NDAQ:SKYE | Press Release - Stockhouse
How do insiders feel about Skye Bioscience Inc.Dividend Hike & Weekly Breakout Opportunity Watchlist - mfd.ru
SKYE Should I Buy - Intellectia AI
What’s the outlook for Skye Bioscience Inc.’s sector2025 Trade Ideas & AI Forecasted Entry and Exit Points - mfd.ru
Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
SKYE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Geopolitics Watch: Does Skye Bioscience Inc meet Warren Buffetts criteriaQuarterly Trade Review & Reliable Price Breakout Alerts - baoquankhu1.vn
1.20%
0.06%
자본화:
|
볼륨(24시간):